Tags

Type your tag names separated by a space and hit enter

Probiotics and prebiotics in ulcerative colitis.

Abstract

The intestinal microbiota is one of the key players in the etiology of ulcerative colitis. Manipulation of this microflora with probiotics and prebiotics is an attractive strategy in the management of ulcerative colitis. Several intervention studies for both the induction and maintenance of remission in ulcerative colitis patients have been performed. Most of these studies evaluated VSL#3 or E. Coli Nissle 1917 and in general there is evidence for efficacy of these agents for induction and maintenance of remission. However, studies are frequently underpowered, lack a control group, and are very heterogeneous investigating different probiotic strains in different study populations. The absence of well-powered robust randomized placebo-controlled trials impedes the widespread use of probiotics and prebiotics in ulcerative colitis. However, given the promising results that are currently available, probiotics and prebiotics may find their way to the treatment algorithm for ulcerative colitis in the near future.

Authors+Show Affiliations

Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands. Electronic address: Lauranne.Derikx@radboudumc.nl.Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada.Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands. Electronic address: Frank.Hoentjen@radboudumc.nl.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27048897

Citation

Derikx, Lauranne A A P., et al. "Probiotics and Prebiotics in Ulcerative Colitis." Best Practice & Research. Clinical Gastroenterology, vol. 30, no. 1, 2016, pp. 55-71.
Derikx LA, Dieleman LA, Hoentjen F. Probiotics and prebiotics in ulcerative colitis. Best Pract Res Clin Gastroenterol. 2016;30(1):55-71.
Derikx, L. A., Dieleman, L. A., & Hoentjen, F. (2016). Probiotics and prebiotics in ulcerative colitis. Best Practice & Research. Clinical Gastroenterology, 30(1), pp. 55-71. doi:10.1016/j.bpg.2016.02.005.
Derikx LA, Dieleman LA, Hoentjen F. Probiotics and Prebiotics in Ulcerative Colitis. Best Pract Res Clin Gastroenterol. 2016;30(1):55-71. PubMed PMID: 27048897.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Probiotics and prebiotics in ulcerative colitis. AU - Derikx,Lauranne A A P, AU - Dieleman,Levinus A, AU - Hoentjen,Frank, Y1 - 2016/02/09/ PY - 2015/11/09/received PY - 2016/02/02/accepted PY - 2016/4/7/entrez PY - 2016/4/7/pubmed PY - 2016/9/23/medline KW - Microbiota KW - Prebiotics KW - Probiotics KW - Ulcerative colitis SP - 55 EP - 71 JF - Best practice & research. Clinical gastroenterology JO - Best Pract Res Clin Gastroenterol VL - 30 IS - 1 N2 - The intestinal microbiota is one of the key players in the etiology of ulcerative colitis. Manipulation of this microflora with probiotics and prebiotics is an attractive strategy in the management of ulcerative colitis. Several intervention studies for both the induction and maintenance of remission in ulcerative colitis patients have been performed. Most of these studies evaluated VSL#3 or E. Coli Nissle 1917 and in general there is evidence for efficacy of these agents for induction and maintenance of remission. However, studies are frequently underpowered, lack a control group, and are very heterogeneous investigating different probiotic strains in different study populations. The absence of well-powered robust randomized placebo-controlled trials impedes the widespread use of probiotics and prebiotics in ulcerative colitis. However, given the promising results that are currently available, probiotics and prebiotics may find their way to the treatment algorithm for ulcerative colitis in the near future. SN - 1532-1916 UR - https://www.unboundmedicine.com/medline/citation/27048897/Probiotics_and_prebiotics_in_ulcerative_colitis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1521-6918(16)00009-3 DB - PRIME DP - Unbound Medicine ER -